ERG Parameter Modeling for Psychiatric Medication Response

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a lack of reliable diagnostic tests for psychiatric disorders, particularly those based on biomarkers, which hinders accurate screening, diagnosis, stratification, and prediction of pharmacological response in patients with conditions like schizophrenia, bipolar disorder, and major depressive disorder.

Innovation Solution

The use of electroretinography (ERG) parameters, analyzed through statistical methods such as logistic regression, to identify specific biomarkers for psychiatric disorders, enabling discrimination between different groups of patients based on their response to medication and shared biological characteristics.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If traditional diagnostic methods (interviews, personality tests, self-reported experiences) are used for psychiatric disorders, then diagnosis can be obtained, but reliability and accuracy are insufficient due to etiological heterogeneity and porous boundaries between DSM categories

Engineering Contradiction:
Improvediagnostic accuracyVSAvoiddiagnostic reliability
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The patent replaces traditional mechanical/clinical diagnostic methods (interviews, personality tests, behavioral observations) with electrophysiological measurement systems. Specifically, it uses electroretinography (ERG) to record electrical responses from retinal cells, and electroencephalography (EEG) to record electrical activity from the brain, substituting subjective clinical assessment with objective biological signal measurement.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the diagnostic parameters from behavioral and subjective metrics to electrophysiological parameters. It measures specific ERG parameters (a-wave amplitude, b-wave amplitude, implicit times) and EEG parameters (power spectral density in different frequency bands, event-related potentials) that reflect underlying neurobiological processes, thereby capturing etiological heterogeneity that traditional methods miss.

Inventive Principle:
Principle #35Parameter changes

2Adaptability or versatility

If DSM categories are used for diagnosis, then classification is achieved, but the porous boundaries and etiological heterogeneity reduce the power of pharmacological and neurobiological studies

Engineering Contradiction:
Improvediagnostic classificationVSAvoidstudy power
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent segments patients into subgroups based on their electrophysiological profiles rather than treating DSM categories as homogeneous. It identifies distinct ERG and EEG patterns within schizophrenia, bipolar disorder, and major depressive disorder, revealing subtypes with different neurobiological characteristics that respond differently to treatments, thereby increasing study power by reducing within-group heterogeneity.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent introduces electrophysiological measurements (ERG and EEG) as intermediary biomarkers that bridge the gap between DSM clinical categories and underlying neurobiological mechanisms. These intermediaries provide objective physiological data that reflect etiological processes, enabling better stratification of patients for pharmacological and neurobiological studies.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Ease of operation

If no biomarkers are used, then diagnosis relies on clinical assessment, but there are no valid and replicable biomarkers to identify etiological heterogeneity within DSM categories

Engineering Contradiction:
Improvediagnostic processVSAvoidbiomarker identification
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The patent replaces the absence of biomarkers with concrete electrophysiological measurements. It implements ERG to measure retinal cell electrical responses and EEG to measure brain electrical activity, providing valid and replicable biomarkers that objectively identify etiological heterogeneity within DSM categories, moving from purely clinical assessment to biomarker-based diagnosis.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

ERG parameters provide accurate discrimination between psychiatric disorder groups with high sensitivity and specificity, facilitating early detection, diagnosis, prognosis, and personalized treatment strategies.

Implementation Method 1

measuring a plurality of ERG parameters, in said subjects

Methodology Applied
Scientific EffectPhotoelectric Effect: Photoelectric Effect

Data Source

PatentEP3747358B1Use of electroretinography (ERG) for the assessment of psychiatric disorders
Publication Date: 2025.10.15 UNIVERSITE LAVAL
  • EP3747358B1 patent drawingFigure 1
  • EP3747358B1 patent drawingFigure 2A~2B
  • EP3747358B1 patent drawingFigure 2C~3A

AI summary

A method of identifying a model, based on one or more ERG parameters, that permits to discriminate between a first group of subjects and a second group of subjects that differ by at least one characteristic, wherein said first group and/or second group of subjects suffer from a psychiatric disorder or a has a predisposition thereto, said method comprising (a) measuring a plurality of ERG parameters in said subjects; (b) performing a logistic regression analysis using the plurality of ERG parameters measured to identify a model that permits to discriminate between a first group and a second group of subjects, wherein the at least one characteristic comprises the response to a psychotropic medication, and wherein said at least one characteristic comprises the response to a psychotropic medication, and wherein said first group of subjects are good responders to a psychotropic medication and said second group of subjects are poor responders to said psychotropic medication.